Results 51 to 60 of about 6,454 (219)
Obesity, EarlyView.ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden +6 more
wiley +1 more source
Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program [PDF]
Body weight reduction; Women; Reproductive stageReducción del peso corporal; Mujeres; Etapa reproductivaReducció del pes corporal; Dones; Etapa reproductivaObjective Increases in adiposity and adverse changes in adipose distribution commonly occur in ...
Ciudin Mihai, Andreea +5 more
core +1 more source
Latest Topic for Clinical Effects of Tirzepatide as Dual GIP/GLP-1 Receptor Agonist [PDF]
, 2022 Treatment for Type 2 Diabetes (T2D) includes incretin hormones, such as glucagon-like peptide-1 (GLP-1) and also glucose-dependent insulinotropic polypeptide (GIP).
185 +4 more
core
Obesity, EarlyView.ABSTRACT Objective This prespecified subpopulation analysis aimed to assess the efficacy and safety of once‐weekly tirzepatide versus placebo alongside lifestyle intervention in Japanese adults with obesity or overweight. Methods Data from 102 Japanese adults in the SURMOUNT‐1 trial with BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 and ≥ 1 weight‐related comorbidity ...
Yasushi Ishigaki +4 more
wiley +1 more source
Tirzepatide-related acute liver injury
European Journal of Case Reports in Internal MedicineTirzepatide, a modified protein containing 39 amino acids, acts as a dual agonist at the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, showing great promise in weight-loss treatment.
Irrum Abdullah +2 more
doaj +1 more source
Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide [PDF]
AimsThis study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m2 and type 1 diabetes (T1D).MethodsThis real‐world study included 250
Al Ozairi, Ebaa +6 more
core +2 more sources
Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi +3 more
wiley +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley +1 more source
A Rare Case of Tirzepatide-Induced Hepatitis: Causality Assessment With the RUCAM Criteria
Annals of Internal Medicine: Clinical CasesTirzepatide is an effective medication that targets both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, resulting in weight loss, improved glycemic control, and better cardiovascular and renal outcomes.
Rayan Tareg Ahmed +3 more
doaj +1 more source